Form 4 for VRTX Vertex Pharmaceuticals

Accepted 2022-05-03 00:00:00 ET · period of report 2022-05-01 · accession 0000899243-22-016336 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-05-03	2022-05-01	VRTX	MCGLYNN MARGARET G	Dir	D - Sale to Iss	—	-921	178	-84%	—
DM	2022-05-03	2022-05-01	VRTX	MCGLYNN MARGARET G	Dir	A - Grant	$0.00	+5,383	5,609	+2,382%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-05-01	D	D	921	—	178	D	—	—	(F1) Upon the vesting of restricted stock units granted to Ms. McGlynn on May 1, 2021, Ms. McGlynn deferred the receipt of 921 shares of common stock and received instead 921 deferred stock units pursuant to the Issuer's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 921 shares of common stock in exchange for an equal number of deferred stock units.
2	Derivative	Stock Option (Right to Buy)	2022-05-01	A	A	4,462	$0.00	4,462	D	$276.17 · 2022-05-01 to 2032-04-30	4,462 Common Stock
3	Derivative	Deferred Stock Units	2022-05-01	A	A	921	—	5,609	D	— · — to —	921 Common Stock	(F1) Upon the vesting of restricted stock units granted to Ms. McGlynn on May 1, 2021, Ms. McGlynn deferred the receipt of 921 shares of common stock and received instead 921 deferred stock units pursuant to the Issuer's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 921 shares of common stock in exchange for an equal number of deferred stock units. (F2) Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on the Issuer's board of directors, (ii) a change of control of the Issuer and (iii) Ms. McGlynn's disability or death.